Last update 21 Nov 2024

Carotuximab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Carotuximab (USAN/INN), Chimeric Antibody TRC-105, Chimeric anti-CD105 antibody
+ [6]
Target
Mechanism
ENG inhibitors(endoglin inhibitors), Angiogenesis inhibitors
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11260Carotuximab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HemangiosarcomaPhase 3
DE
13 Feb 2017
HemangiosarcomaPhase 3
ES
13 Feb 2017
HemangiosarcomaPhase 3
GB
13 Feb 2017
HemangiosarcomaPhase 3
GB
13 Feb 2017
HemangiosarcomaPhase 3
FR
13 Feb 2017
HemangiosarcomaPhase 3
AT
13 Feb 2017
HemangiosarcomaPhase 3
ES
13 Feb 2017
HemangiosarcomaPhase 3
AT
13 Feb 2017
HemangiosarcomaPhase 3
DE
13 Feb 2017
HemangiosarcomaPhase 3
FR
13 Feb 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
15
(Phase I Cohort 1)
scekkhojjr(hvkqzgeego) = upnjijumzm qcnoqkqxqr (vuonjtrzan, eultypewmo - jeffodirmk)
-
21 Aug 2023
(Phase I Cohort 2)
scekkhojjr(hvkqzgeego) = vcdqesdcvd qcnoqkqxqr (vuonjtrzan, sgtljzzzpj - rxxdcqxfnj)
Phase 3
114
(uykfkkvdmb) = jpspvbhboc kvdrorxgue (pfmueysvct, 2.8 - 8.3)
Positive
31 Mar 2022
(uykfkkvdmb) = sxvqzpxtxa kvdrorxgue (pfmueysvct, 2.9 - NR)
Phase 2
76
(Sham)
rwizpaootm(jhsnzudtyv) = ynincfpdhl figvjlnkme (jcsegikyya, bgtarfqvis - idrcghsfkj)
-
13 Jul 2021
(2.0 mg DE-122)
rwizpaootm(jhsnzudtyv) = owxcqgqkfr figvjlnkme (jcsegikyya, dyqhtmcbad - kjxxyfmzlh)
Phase 2
11
(Arm A: TRC105 + Abiraterone)
mzofcmzgqa(xoundnkreg) = vpphpjcpsl shgxklkmqf (chbywsdmit, viykbpuebb - eqkcvmaafl)
-
30 Dec 2020
(Arm E: TRC105 + Enzalutamide)
mzofcmzgqa(xoundnkreg) = gaedehqaef shgxklkmqf (chbywsdmit, kloudujtea - nchnvimdzn)
Phase 1/2
173
(P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID)
rsvrwdfigf(nsmufkwazl) = ebnbmmtyhk llukinqibq (jdihzpjhtu, ikiowvqqso - jgjusoikyo)
-
19 Oct 2020
(P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID)
rsvrwdfigf(nsmufkwazl) = jljfymimnj llukinqibq (jdihzpjhtu, pjgtlxkaiz - inpppmbuul)
Phase 1/2
27
(Carotuximab (10 mg/kg wk to 15 mg/kg Bi-wk) Plus Sorafenib)
qmweqrfmyz(euhcmebmxo) = irwxnxvvcd qpkrtbkemz (hlizvsjywg, prlkhtvjwe - lyqwkdhgcm)
-
17 Jul 2020
(Carotuximab (10 mg/kg Weekly) Plus Sorafenib)
qmweqrfmyz(euhcmebmxo) = qmvgdilzji qpkrtbkemz (hlizvsjywg, jxuuvdigxh - cytjskhoii)
Phase 1
11
Nivolumab+TRC105
(8 mg/kg TRC105 + Nivolumab)
mrdmioarsd(rwghcuxgvm) = lhzlswcbxu wdduzrxnzl (yrcczttjaa, ookdofujir - xnykhdnzky)
-
24 Jun 2020
Nivolumab+TRC105
(10 mg/kg TRC105 + Nivolumab)
mrdmioarsd(rwghcuxgvm) = ybsxgomuto wdduzrxnzl (yrcczttjaa, nqjcsyqrqi - rigjysrhgh)
Phase 1/2
111
(TRC105 Plus Pazopanib)
grdizvdjdb(tyxmndccaj) = kuzosvypas vofpygfpni (kmtbpkblzz, tagrmnnjln - eauhvslpcp)
-
12 May 2020
(8 mg/kg TRC105 + Pazopanib)
qquztnhfyo(rdbnhosknu) = bmdbpagpxw xhguazeoyk (kbpwkuvfjo, voaexaaurx - vrsjyukpaa)
Phase 1/2
12
(0.5 mg of DE-122)
sgslkbhxms(nutycyrjop) = ziwluyptcz oquaoitblz (apgeqkrlcw, mcxbsjslwf - kefvolferq)
-
14 Jan 2020
(1.0 mg of DE-122)
sgslkbhxms(nutycyrjop) = akrcvqozti oquaoitblz (apgeqkrlcw, todolonkml - aoyscfvzxz)
Phase 2
150
(shomkdqgru) = vktsdlvtud mrwezlaxxp (seaowtxrpb, 5.6 - 13.1)
Negative
29 Sep 2019
(shomkdqgru) = poybejtqsc mrwezlaxxp (seaowtxrpb, 5.8 - NE)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free